Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolving the Paradox of Training in Preventive Medicine.

American journal of preventive medicine·2025
Same author

The Slow-Moving Crisis of Training in Occupational and Environmental Medicine.

Journal of occupational and environmental medicine·2024
Same author

Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study.

The European respiratory journal·2024
Same author

Use of sugar in coffee and tea and long-term risk of mortality in older adult Danish men: 32 years of follow-up from a prospective cohort study.

PloS one·2023
Same author

Increased Mortality Associated With Disability Among Workers' Compensation Claimants With Upper Extremity Neuropathy.

Journal of occupational and environmental medicine·2023
Same author

Historical shift in pathological type of progressive massive fibrosis among coal miners in the USA.

Occupational and environmental medicine·2023

Related Experiment Video

Updated: May 16, 2026

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Combined effect of lung function level and decline increases morbidity and mortality risks.

Penelope Baughman1, Jacob L Marott, Peter Lange

  • 1Division of Respiratory Disease Studies, Surveillance Branch, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA. goz2@cdc.gov

European Journal of Epidemiology
|December 15, 2012
PubMed
Summary

Even with normal lung function, a rapid decline in forced expiratory volume in one second (FEV(1)) significantly increases risks for chronic obstructive pulmonary disease (COPD) morbidity and mortality. This highlights the importance of monitoring lung function decline in identifying high-risk individuals.

More Related Videos

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Experiment Videos

Last Updated: May 16, 2026

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Pulmonary Medicine
  • Epidemiology
  • Biostatistics

Background:

  • Lung function level and its rate of decline are established predictors of morbidity and mortality.
  • Identifying individuals at high risk for respiratory and cardiovascular diseases is crucial for targeted interventions.

Purpose of the Study:

  • To evaluate the combined impact of lung function level and decline on predicting risks of chronic obstructive pulmonary disease (COPD) morbidity and mortality.
  • To identify high-risk groups by analyzing the interplay between baseline forced expiratory volume in one second (FEV(1)) and its rate of decline.

Main Methods:

  • Utilized longitudinal spirometry data from the Copenhagen City Heart Study (n=10,457).
  • Employed Cox proportional hazards models to estimate 16-21 year risks of COPD morbidity, COPD/coronary heart disease mortality, and all-cause mortality.
  • Stratified analyses were performed by gender, smoking status, and baseline age (≤45 and >45) to assess hazard ratios (HRs) and 95% confidence intervals (CIs).

Main Results:

  • Increasing quartiles of FEV(1) decline were associated with elevated HRs for COPD morbidity, particularly in individuals with FEV(1) below 100% predicted but at or above the lower limit of normal (LLN).
  • Steepest FEV(1) decline showed significantly increased risks for males (HR 5.11), females (HR 11.63), and never smokers (HR 3.09).
  • Significant increasing trends in mortality risks were observed across declining FEV(1) levels, especially in younger individuals (≤45 years) and never smokers with rapid lung function decline.

Conclusions:

  • Even individuals with 'normal' lung function (FEV(1) at or above LLN) face significantly increased mortality risks if they experience excessive FEV(1) decline.
  • Monitoring the rate of lung function decline is essential for identifying high-risk populations, including never smokers and younger adults.
  • The combined assessment of lung function level and decline offers a more refined approach to risk stratification for respiratory and cardiovascular outcomes.